Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.

<p>Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.</p>

Gardado en:

Detalles Bibliográficos
Autor Principal:	Seyed Reza Mousavi (13223324) (author)
Outros autores:	Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author)
Publicado:	2025
Subjects:	Medicine Cell Biology Neuroscience Physiology Pharmacology Biotechnology Immunology Science Policy Mental Health patients received either day monitoring period total antivenom consumption treating snakebite envenomation antivenom units administered razi antivenom group snakebite envenomation razi antivenom razi group antivenom infusion 49 units 40 units snafab antivenom razi antivenoms snafab group serum sickness recovery rate primary endpoint muscle weakness mean number may 15th april 17th anaphylactic shock adverse events 98 %). 92 ). 27 ). 100 percent
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares